Th e costs of progressive chronic kidney disease (CKD) in terms of patient morbidity, mortality, and, of course, its economic burden have been discussed repeatedly. On one point there is unanimity, namely, that the frequency of CKD continues to grow. For example, on the basis of indices of health collected from nationally representative samples of adults in the United States during the 1999 -2004 National Health and Nutrition Examination Survey (NHANES), it was concluded that the prevalence of stages 1 -4 CKD was as high as 13 % ! 1 Such data have understandably sparked interest in identifying mechanisms that cause the progressive loss of kidney function (that is, progression) and in devising treatments to prevent progression. Th ere have been at least partial successes: pharmacologic inhibition of the renin -angiotensin -aldosterone system was shown to improve the outcome of CKD in rodents and can slow progression in patients with different types of CKD. 2 On the basis of the established benefi ts of protein-restricted diets in improving the mortality and renal pathology that occur in rodent models of CKD, 3 the influence of dietary protein restriction on progression has also been studied. Th is strategy slowed progression in rodent models of CKD and exhibited mixed outcomes with regard to slowing progression in nondiabetic CKD patients. 4, 5 Gao and colleagues 6 (this issue) describe their results detailing how dietary manipulation can initiate an unexpected mechanism that suppresses the pathologic changes that occur in the kidneys of a rat model of CKD (subtotal nephrectomy). Th eir treatment was directed at addressing two questions: Would ketoacids infl uence the course of CKD beyond what can be attributed to the supplying of a nitrogenfree supplement of essential amino acids? Secondly, why is renal interstitial fi brosis prominent in CKD? Th e fi rst question was raised because there is evidence in humans that the ketoacid of leucine, namelyketoisocaproate, improves protein metabolism to a greater degree than leucine does, a response that occurs even when -ketoisocaproate is administered without other ketoacids or amino acids. 7 Th eir attempts to address the second question involved assessment of changes in the renal expression of the transcription factor Kruppellike factor-15 (KLF15) and how it aff ected the development of CKD-stimulated fi brosis in the kidney. Th e latter experiments were undertaken because the rapidity of progression is generally related to the degree of interstitial infl ammation and fibrosis, and, in the heart, KLF15 can reduce the transcription of connective tissue growth factor. KLF15 abundance was reduced in the remnant kidneys of CKD rats fed normal chow containing 22 % protein. In the next stage, the authors examined whether dietary protein restriction and ketoacids would reduce fi brosis in the remnant kidney. Th e experimental plan was straightforward and was based on assessments of diff erences in histologic damage and indices of kidney function in CKD rats fed the 22 % protein diet versus CKD rats fed 6 % protein (low-protein diet (LPD)) or 5 % protein and 1 % ketoacids (LPD-KA). Th e results confi rmed that the LPD reduced both proteinuria and the increase in blood urea nitrogen; the authors also found a reduced degree of macrophage infi ltration and tubulointerstitial lesions, including interstitial fi brosis. 4 In addition, mRNA levels of infl ammatory genes in kidneys of CKD rats were lower in rats fed the LPD. All these benefi cial responses were improved further in rats fed the ketoacid-supplemented diet. A novel result was the increase in the expression of KLF15 (mRNA and protein) in kidneys of CKD rats fed the LPD or the LPD-KA diet as compared with the normal protein chow. Notably, this increase in KLF15 expression in remnant kidneys was associated with improvements in both pathologic changes in the kidney and decreased expression of type IV collagen and fibronectin. Other experimental results included a demonstration that the LPD raised renal levels of KLF15 mRNA in mesangial cells, while KLF15 knockout mice exhibited heightened susceptibility to injury. These responses support the authors ' conclusions that KLF15 is involved in the pathogenesis of renal interstitial fi brosis in CKD ( Figure 1 ) .
Th ese fi ndings are provocative, and, like many impressive results obtained in studies of animal models, they prompt more investigations to address several questions. First addressed, but the available evidence suggests that the LPD or the LPD-KA diet did not improve renal function, as the serum creatinine values were not statistically different. Second, what is the mechanism that underlies the reduction in interstitial damage associated with dietary protein restriction? Intriguing possibilities include inhibition of responses to metabolic acidosis and / or improvement of defects in insulin -insulin-like growth factor-1 cellular signaling that are due to renal insufficiency. Regarding acidosis, the metabolism of sulfa-containing amino acids in dietary protein and the degree of renal insuffi ciency are the major determinants of the degree of acidosis in CKD. In the study by Gao et al. , 6 there was an increase in bicarbonate stores in CKD rats fed the LPD or the LPD-KA diet as compared with the 22 % protein diet. This would counteract the infl uence of acidosis and explain why the authors found essentially normal values of serum bicarbonate in CKD rats fed the protein-restricted diets. Th is result is relevant because correction of acidosis could improve renal function. For example, results from a recent clinical trial testing responses to an oral supplement of sodium bicarbonate revealed that the therapy slowed the loss of kidney function. 8 Th e suggestion that there is a role for defects in intracellular signaling as a mechanism linking KLF15 to renal fi brosis arises from the observation that KLF15 has been identifi ed as a regulator of gluconeogenesis and adipocyte diff erentiation. Not only is it established that CKD interferes with the insulin -insulin-like growth factor-1 signaling pathway, but we also recently found that impaired insulin-like growth factor-1 signaling can stimulate the development of fibrosis in muscle, especially when CKD is present. 9 Th us, it is tempting to speculate that the dietary manipulation used by Gao et al. 6 might reduce the development of fi brosis in other organs as well as in the kidney. Third, activated fi broblasts contribute to the excessive production of extracellular matrix. However, the origin of these fibroblasts remains controversial. We recently found (our unpublished results) that bone marrowderived fibroblasts contribute to the pathogenesis of fi brosis in the kidney. As Gao et al. 6 found that the LPD or LPD-KA diet reduces the degree of macrophage infiltration in the kidney, it would be interesting to determine whether these diets also inhibit infiltration of bone marrow-derived fi broblasts.
Fortunately, long-term experience with ketoacid-supplemented, low-protein diets indicates they are safe and effective in ameliorating metabolic complications of CKD, making this type of therapy at least provisionally available. 10 However, the results of Gao et al. are not suffi cient to allow extrapolation of the responses into treatment strategies for patients with CKD. First, this type of dietary therapy is nonspecifi c, as it will change the function of many organs, so methods of specifi cally testing how changes in KLF15 infl uence changes in kidney function are needed. In addition, clinically available methods of determining whether other types of kidney diseases are associated with low levels of KLF15 in the kidneys of experimental animals and humans will be required. Aft er these requirements are satisfied, a long-term analysis of the impact of raising KLF15 on other organs and kidney functions would be needed. For these reasons, these novel and tempting results must be considered preliminary with regard to influencing the treatment of CKD patients.
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